SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Playing Hammered Stocks for a Bounce, But How? -- Ignore unavailable to you. Want to Upgrade?


To: Mark Jenkins who wrote (75)1/29/1998 9:01:00 AM
From: Mark Jenkins  Read Replies (4) | Respond to of 159
 
08:54 ET Cor Therapeutics (CORR) 20: Stk indicated 11 pts lower after
biotech company's INTEGRILIN drug received marketing approval for use in the setting of coronary angioplasty, but failed to win approval for treatment of acute coronary syndromes, which is a much larger market.



To: Mark Jenkins who wrote (75)1/29/1998 9:28:00 AM
From: Keith Lenart  Read Replies (2) | Respond to of 159
 
CORR looks like a very good play. Good luck everyone!